» Articles » PMID: 39329977

Effects of Curcumin on Radiation/Chemotherapy-Induced Oral Mucositis: Combined Meta-Analysis, Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2024 Sep 27
PMID 39329977
Authors
Affiliations
Soon will be listed here.
Abstract

The study aims to investigate the effects of curcumin on radiation/chemotherapy-induced oral mucositis (R/CIOM) and preliminarily explore its mechanism. Randomized controlled trials were identified from the PubMed, Embase, Web of Science, Cochrane Library, Medline, and Google Scholar databases. RevMan 5.4 was used for statistical analysis to calculate the combined risk ratios (RRs). The mechanism was analyzed through network pharmacology, molecular docking, and a molecular dynamics simulation. The targets of curcumin were collected in HERB, PharmMapper, Targetnet, Swiss Target Prediction, and SuperPred. OMIM, GeneCards, and Disgenet were used to collect relevant targets for R/CIOM. Cytoscape software 3.8.0 was used to construct the component-target-pathway network. Protein-Protein Interaction (PPI) networks were constructed using the STRING database. GO and KEGG enrichment analyses were performed by Metascape. AutoDock Vina 4.2 software was used for molecular docking. The molecular dynamics simulation was performed by Gromacs v2022.03. It is found that 12 studies involving 565 patients were included. Meta-analyses showed that curcumin reduced the incidence of severe R/CIOM (RR 0.42 [0.24, 0.75]) and the mean severity of R/CIOM (MD -0.93 [-1.34, -0.52]). Eleven core target genes were identified in the treatment of R/CIOM with curcumin. The results of molecular docking and the molecular dynamics simulation showed that curcumin had strong binding energy and stability with target proteins including MAPK3, SRC, and TNF. Overall, these findings suggest curcumin can effectively improve severe R/CIOM, perhaps by affecting MAPK3, SRC, and TNF.

Citing Articles

In Silico Discovery of a Novel PI3Kδ Inhibitor Incorporating 3,5,7-Trihydroxychroman-4-one Targeting Diffuse Large B-Cell Lymphoma.

Jia W, Liu J, Cheng X, Li X, Ma Y Int J Mol Sci. 2024; 25(20).

PMID: 39457034 PMC: 11508633. DOI: 10.3390/ijms252011250.

References
1.
de Vries J, Poelman A, Sidorenkov G, Festen S, de Bock G, Langendijk J . The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer. Oral Oncol. 2022; 130:105933. DOI: 10.1016/j.oraloncology.2022.105933. View

2.
Ozpinar G, Peukert W, Clark T . An improved generalized AMBER force field (GAFF) for urea. J Mol Model. 2010; 16(9):1427-40. DOI: 10.1007/s00894-010-0650-7. View

3.
Kotha R, Luthria D . Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. Molecules. 2019; 24(16). PMC: 6720683. DOI: 10.3390/molecules24162930. View

4.
Ramezani V, Ghadirian S, Shabani M, Boroumand M, Daneshvar R, Saghafi F . Efficacy of curcumin for amelioration of radiotherapy-induced oral mucositis: a preliminary randomized controlled clinical trial. BMC Cancer. 2023; 23(1):354. PMC: 10108802. DOI: 10.1186/s12885-023-10730-8. View

5.
Dulbecco P, Savarino V . Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol. 2014; 19(48):9256-70. PMC: 3882399. DOI: 10.3748/wjg.v19.i48.9256. View